Skip to main content
Clinical Trials/NCT07367568
NCT07367568
Recruiting
Not Applicable

Comparison of Costotransverse Foramen Block With Erector Spinae Plane Block in Modified Radical Mastectomy: A Randomized Controlled Trial

National Cancer Institute, Egypt1 site in 1 country110 target enrollmentStarted: January 24, 2026Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
National Cancer Institute, Egypt
Enrollment
110
Locations
1
Primary Endpoint
Total morphine consumption

Overview

Brief Summary

This study aims to compare the costotransverse foramen block with erector spinae plane block in modified radical mastectomy.

Detailed Description

Postoperative pain following modified radical mastectomy (MRM) is a considerable consequence, impacting the ipsilateral upper limbs, axillae, and thorax, resulting in diminished functional ability and substantial economic and societal repercussions.

Erector spinae plane block (ESPB), an interfascial block, minimizes nerve and vessel injury by allowing local anesthetics to diffuse across relevant spaces; it is technically simpler and has shown benefits in reducing postoperative analgesic use and pain scores.

A novel technique, the costotransverse foramen block (CTFB), is one type of Inter-transverse process (ITP) blocks. This technique entails the anterior dispersion of the local anesthetic injectate into the paravertebral region, affecting the thoracic nerve at the injection site and neighboring levels, while exhibiting negligible posterior diffusion of dye to the deep back muscles

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult females \> 18 years and ≤ 65 years old.
  • American Society of Anesthesiologists (ASA) physical status П-III.
  • Body mass index (BMI) 18-35 kg/m
  • Scheduled for modified radical mastectomy.

Exclusion Criteria

  • Known allergy or hypersensitivity to local anesthetic agents.
  • Active infection at the injection site (e.g., cellulitis, abscess).
  • Coagulopathy or ongoing anticoagulant/antiplatelet therapy \[International Normalized Ratio (INR) \> 1.5 or platelet count \< 100,000/µL\].
  • Severe respiratory, cardiac, hepatic, or renal disease.
  • Morbid obesity.
  • Severe cognitive impairment or uncooperative behavior that could interfere with block placement.

Arms & Interventions

CTFB Group

Experimental

Patients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%.

Intervention: Costotransverse foramen block (Other)

ESPB Group

Experimental

Patients will receive an ipsilateral ultrasound-guided erector spinae plane block with injection of 20 ml bupivacaine 0.25%.

Intervention: Erector spinae plane block (Other)

Outcomes

Primary Outcomes

Total morphine consumption

Time Frame: 24 hours postoperatively

If the numeric rating scale (NRS) is ≥ 4, an IV morphine dose (3 mg) will be provided Paracetamol 1 gm and ketorolac 30 mg will be administered every 8 hours postoperatively.

Secondary Outcomes

  • Degree of pain(48 hours postoperatively)
  • Time to first request of rescue analgesia(24 hours postoperatively)
  • Intraoperative fentanyl consumption(Intraoperatively)
  • Mean arterial pressure(4 hours postoperatively)
  • Heart rate(4 hours postoperatively)
  • Incidence of adverse effects(24 hours postoperatively)

Investigators

Sponsor
National Cancer Institute, Egypt
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mai Mohamed El Rawas

Assistant professor of Anaesthesia, Intensive Care and Pain Management, National Cancer Institute, Cairo University Cairo University, Cairo, Egypt.

National Cancer Institute, Egypt

Study Sites (1)

Loading locations...

Similar Trials